BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

AstraZeneca PLC (AZN) Neuroscience Unit Inks Pact With Vanderbilt University


1/15/2013 7:24:25 AM

AstraZeneca plc (NYSE: AZN) has signed a research deal with Vanderbilt University to identify potential treatments for psychosis and other psychiatric symptoms associated with diseases like Alzheimer’s and schizophrenia. The UK-based drug giant’s Neuroscience Innovative Medicines Unit headquartered in Cambridge, Mass. and Cambridge, England, has exclusively licensed rights to compounds developed by the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) that act on a certain brain receptor. Vanderbilt will receive an upfront payment research funding for two years as well as milestone payments and sales royalties of any drugs that are approved, but the dollar figure of the deal was not disclosed. “AstraZeneca is interested in pursuing research collaborations across all areas of neuroscience research where the science is compelling,” Dr. Mike Poole, vice president of the AstraZeneca Neuroscience Innovative Medicines Unit, said in a statement. “We believe that combining AstraZeneca’s deep experience in drug development and translational science with VCNDD’s expertise in drug discovery is an important step toward bringing new medicines forward for people who are suffering from neurodegenerative diseases."


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES